Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Bemnifosbuvir
Clinical data | |
---|---|
Other names | AT-527, AT-511 |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C24H33FN7O7P |
Molar mass | 581.542 g·mol−1 |
3D model (JSmol) | |
| |
|
Bemnifosbuvir (AT-527, RO7496998) is an antiviral drug invented by Atea Pharmaceuticals and licensed to Roche for clinical development, a novel nucleotide analog prodrug originally developed for the treatment of hepatitis C. AT-527 is the orally bioavailable hemisulfate salt of AT-511, which is metabolised in several steps to the active nucleotide triphosphate AT-9010, acting as an RNA polymerase inhibitor and thereby interfering with viral replication. AT-527 has been researched for the treatment of coronavirus diseases such as that produced by SARS-CoV-2. It showed good results in early clinical trials but had inconsistent results at later stages, so the planned Phase 3 trials are being redesigned and results are not expected until late 2022.
See also
Hepatitis C |
|
||||||||
---|---|---|---|---|---|---|---|---|---|
Hepatitis D | |||||||||
Picornavirus | |||||||||
Anti-influenza agents | |||||||||
Multiple/general |
|
||||||||
|